3 Stocks Pushing The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 16,578 as of Thursday, May 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,778 issues advancing vs. 1,187 declining with 180 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Heartware International ( HTWR), up 12.9%, Catamaran ( CTRX), up 11.5%, Wright Medical Group ( WMGI), up 9.7%, Hologic ( HOLX), up 8.1% and Waters ( WAT), up 1.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Masimo ( MASI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Masimo is down $2.79 (-10.4%) to $23.97 on heavy volume. Thus far, 1.4 million shares of Masimo exchanged hands as compared to its average daily volume of 459,900 shares. The stock has ranged in price between $23.70-$26.29 after having opened the day at $26.29 as compared to the previous trading day's close of $26.76.

Masimo Corporation, a medical technology company, develops, manufactures, and markets various noninvasive patient monitoring products worldwide. Masimo has a market cap of $1.5 billion and is part of the health care sector. The company has a P/E ratio of 28.0, above the S&P 500 P/E ratio of 17.7. Shares are down 9.8% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Masimo a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Masimo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Masimo Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Charles River Laboratories International In ( CRL) is down $2.44 (-4.5%) to $51.28 on heavy volume. Thus far, 983,422 shares of Charles River Laboratories International In exchanged hands as compared to its average daily volume of 607,600 shares. The stock has ranged in price between $51.08-$55.00 after having opened the day at $54.29 as compared to the previous trading day's close of $53.72.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. Charles River Laboratories International In has a market cap of $2.7 billion and is part of the health care sector. The company has a P/E ratio of 28.8, above the S&P 500 P/E ratio of 17.7. Shares are up 3.8% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Charles River Laboratories International In a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Charles River Laboratories International In as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Charles River Laboratories International In Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Becton Dickinson ( BDX) is down $1.07 (-0.9%) to $111.96 on average volume. Thus far, 589,161 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 892,200 shares. The stock has ranged in price between $111.07-$113.06 after having opened the day at $112.93 as compared to the previous trading day's close of $113.03.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $21.7 billion and is part of the health care sector. The company has a P/E ratio of 24.9, above the S&P 500 P/E ratio of 17.7. Shares are up 1.5% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Becton Dickinson a buy, 2 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike